保法止品牌怎么样 申请店铺

保法止是唯一经过美国FDA认证治疗男性脱发的非那雄胺药物。保法止主要成分为非那雄胺，它是一种合成的甾体化合物，是雄激素睾酮代谢成为双氢睾酮过程中的细胞内酶Ⅱ型5a还原酶的特异性抑制剂，通过对该酶的抑制，使得患者头皮以及血清中的双氢睾酮浓度下降，从而抑制头皮毛囊变小，逆转脱发过程。保法止是一种专门用于治疗雄激素性秃发（男性秃发），能有效促进头发生长并防止继续脱发的内服药物。

默沙东公司是世界著名的跨国制药企业，总部设于美国新泽西州（在美国名为默克公司），全球雇员超过83，000人。默沙东以科研为本，致力于医学研究、开发和销售人用及兽用医药产品，其行销网络遍及美国、欧洲、中南美洲以及亚太共70个国家和地区，设有31家工厂及17个物流发货中心，目前在全球生产及销售的默沙东产品已有150多种，2007年销售额242亿美元。其2012年收入为473亿美元，同年的研发支出为81.68亿美元。

2009年3月9日，默沙东宣布将以411亿美元，并购其竞争对手先灵葆雅，两家公司在一则联合声明中公布了以上消息，合并后的公司将沿用默沙东公司的名称。默沙东总裁、首席执行官理查德?克拉克(RichardT.Clark)将负责领导新公司。并购支付方式为现金加股票，并购后默沙东将成为全美第二大制药公司。

1992年默沙东(中国)有限公司正式成立。1994年，默沙东与杭州华东医药集团有限公司成立了合资企业——杭州默沙东制药有限公司。默沙东在中国市场主要销售17个产品，其中大部分产品已在杭州工厂分装或生产。产品覆盖领域广泛，在降血压、调节血脂、治疗前列腺增生、哮喘、骨关节炎、骨质疏松、男性脱发和艾滋病等多个治疗领域方面均居领先地位。还有一系列疫苗预防甲肝、麻疹风疹腮腺炎及肺炎球菌、流感嗜血杆菌引起的疾病。目前默沙东在中国已有员工4500余名，在全国设有14个办事处，在未来默沙东中国还将继续扩大自己的员工队伍，并制定了“制胜中国”的宏伟计划，寄望在中国市场取得匹配其全球制药巨头地位的成绩。

Baofazhi is the only finasteride drug certified by FDA to treat male hair loss. Finasteride is the main component of baofazhi, which is a synthetic steroid compound. It is a specific inhibitor of intracellular enzyme type Ⅱ 5A reductase in the process of androgen testosterone metabolizing into dihydrotestosterone. Through the inhibition of this enzyme, the concentration of dihydrotestosterone in patients' scalp and serum is decreased, so as to inhibit the hair follicle of scalp to become smaller and reverse the hair loss process. Baofazhi is a kind of internal medicine specially used to treat androgenic alopecia (male alopecia), which can effectively promote hair growth and prevent hair loss. Merck is a world-famous multinational pharmaceutical company, headquartered in New Jersey (Merck in the United States), with more than 83000 employees worldwide. Based on scientific research, MSD is committed to medical research, development and sales of human and veterinary medical products. Its marketing network covers 70 countries and regions in the United States, Europe, central and South America and Asia Pacific. It has 31 Factories and 17 logistics and delivery centers. Currently, there are more than 150 kinds of MSD products produced and sold in the world, with a sales volume of US $24 billion 200 million in 2007. Its revenue in 2012 was US $47.3 billion, and its R & D expenditure in the same year was US $8.168 billion. On March 9, 2009, MSD announced that it would acquire its competitor Schering plough for us $41.1 billion. The two companies announced the above information in a joint statement. The merged company will use the name of MSD. Richard T. Clark, President and chief executive of MSD, will lead the new company. The payment method of M & A is cash plus stock. After M & A, MSD will become the second largest pharmaceutical company in the United States. In 1992, MSD (China) Co., Ltd. was officially established. In 1994, MSD and Hangzhou Huadong Pharmaceutical Group Co., Ltd. established a joint venture - Hangzhou MSD Pharmaceutical Co., Ltd. MSD mainly sells 17 products in the Chinese market, most of which have been repackaged or produced in Hangzhou factory. The products cover a wide range of fields, and take the leading position in many fields, such as lowering blood pressure, regulating blood lipid, treating prostatic hyperplasia, asthma, osteoarthritis, osteoporosis, male hair loss and AIDS. There are also a series of vaccines to prevent diseases caused by hepatitis A, measles, rubella, mumps, pneumococcus and Haemophilus influenzae. At present, MSD has more than 4500 employees in China and has 14 offices across the country. In the future, MSD China will continue to expand its staff and develop a grand plan of "winning China", hoping to achieve results matching its position as a global pharmaceutical giant in the Chinese market.

本文链接： https://brand.waitui.com/521bbf9e3.html 联系电话：02122118888